Further research may clarify how these peptides can safely enhance libido and improve sexual health
India, 2022) 3,170 (3 mg), 3,520 (7 mg), 3,870 (14 mg) MOUNJARO (Tirzepatide GLP & GIP agonist) Eli Lilly Weekly injection (starting 2.5 mg) Dual agonist breakthrough Not yet approved ZEBOUND (Tirzepatide) Eli Lilly Weekly injection (starting 2.5 mg) Approved for weight loss (US, 2023) ~$1,060/4 injections (88,000) Not available VICTOZA (Liraglutide GLP-1) Novo Nordisk Daily injection: 0.6 mg For Type 2 diabetes (India, 2010) 5,324/month APLEVANT (Dulaglutide GLP-1) Eli Lilly (sold by Lupin in India) Weekly injection: 0.75 mg For Type 2 diabetes (India, 2018) 5,497 per pre-filled pen BYETTA (Exenatide GLP-1) Eli Lilly Twice-daily injection: 0.005 mg Approved for Type 2 diabetes (2007) 6,957 for 60-dose pen Pipeline & Research Therapies GLOO34 (Sun Pharma GLP-1 agonist) Under development in India for obese & overweight patients without diabetes
Not intended for medical, diagnostic, or therapeutic use
And the entire experience is backed by a vendor with 5-star Trustpilot reviews, a large customer base, and an active social media community that confirms consistent quality across thousands of orders
As well, in real-world scenarios, such as described by Brindisi et al, it is mentioned a reduction in pleasure and taste perception in overweight and people with obesity with poor type 2 diabetes control, probably by lowering the detection threshold of sweet flavors, becoming more sensitive to them, resulting in aversion for this flavor (175)
